Immunomodulator combination

This page covers all Immunomodulator combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Histamine receptors (H1, H2, H3, H4) and IL-2 receptor, T-cell maturation pathway; interferon-alpha receptor (IFNAR).

Targets

Histamine receptors (H1, H2, H3, H4) and IL-2 receptor · T-cell maturation pathway; interferon-alpha receptor (IFNAR)

Marketed (2)

• histamine dihydrochloride and IL-2 · Cytovia, Inc. · Oncology
  This combination therapy stimulates immune cells through histamine receptor signaling and IL-2-mediated T-cell activation to enhance anti-tumor immunity.
• Thymosin alpha1 & Pegylated Interferon-alpha2a · Seoul National University Hospital · Immunology, Oncology, Infectious Disease
  This combination enhances immune response by stimulating T-cell maturation and proliferation (thymosin alpha1) while amplifying interferon-mediated antiviral and anti-tumor effects (pegylated interferon-alpha2a).